Dorzolamide opthalmic - Oculis Pharma
Alternative Names: DorzNP; OC 201Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Oculis Pharma
- Class Antiglaucomas; Eye disorder therapies; Small molecules; Sulfonamides; Thiophenes
- Mechanism of Action Carbonic anhydrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 18 Feb 2022 Discontinued - Phase-II for Glaucoma in Iceland (Ophthalmic) (Oculis Pharma pipeline, February 2022)
- 01 Jan 2015 Phase-II clinical trials in Glaucoma in Iceland (Ophthalmic)